We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+8.96%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$73.6B
AUM Growth
+$1.15B
(+1.6%)
Cap. Flow
-$3.6B
Cap. Flow
% of AUM
-4.89%
Top 10 Holdings %
Top 10 Hldgs %
20.8%
Holding
3,102
New
50
Increased
790
Reduced
2,114
Closed
100
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NXP Semiconductors
NXPI
|
+$38.7M |
| 2 |
International Flavors & Fragrances
IFF
|
+$27.4M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$14.7M |
| 4 |
ConocoPhillips
COP
|
+$14.5M |
| 5 |
Royalty Pharma
RPRX
|
+$9.46M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$269M |
| 2 |
Microsoft
MSFT
|
+$172M |
| 3 |
Amazon
AMZN
|
+$114M |
| 4 |
Walt Disney
DIS
|
+$62.4M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$61.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.61% |
| 2 | Financials | 14.26% |
| 3 | Healthcare | 12.86% |
| 4 | Consumer Discretionary | 12.27% |
| 5 | Industrials | 9.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1676
Vir Biotechnology
VIR
$1.49B
| $3.1M | ﹤0.01% |
60,385
-5,050
| -8% | -$272K |
|
1677
Adaptive Biotechnologies
ADPT
$3.97B
| $3.09M | ﹤0.01% |
76,682
-9,246
| -11% | -$500K |
|
1678
MACOM Technology Solutions
MTSI
$23.7B
| $3.08M | ﹤0.01% |
53,178
-4,678
| -8% | -$290K |
|
1679
Scholastic
SCHL
$792M
| $3.08M | ﹤0.01% |
102,358
+1,200
| +1% | +$33.8K |
|
|
VISN
1680
Vistance Networks Inc
VISN
$2.52B
| $3.08M | ﹤0.01% |
200,346
-7,970
| -4% | -$119K |
|
1681
Caleres
CAL
$487M
| $3.07M | ﹤0.01% |
140,833
+1,021
| +0.7% | +$17.4K |
|
1682
Century Aluminum
CENX
$5.07B
| $3.07M | ﹤0.01% |
173,725
+961
| +0.6% | +$13.7K |
|
1683
Children's Place
PLCE
$59.8M
| $3.07M | ﹤0.01% |
44,007
-198
| -0.4% | -$13.9K |
|
|
AEGN
1684
DELISTED
Aegion Corp
AEGN
| $3.07M | ﹤0.01% |
106,663
-172
| -0.2% | -$4.11K |
|
1685
Quanex
NX
$1.01B
| $3.07M | ﹤0.01% |
116,888
+1,704
| +1% | +$42.5K |
|
1686
AngioDynamics
ANGO
$649M
| $3.06M | ﹤0.01% |
130,773
+185
| +0.1% | +$3.74K |
|
1687
Alkermes
ALKS
$8.25B
| $3.06M | ﹤0.01% |
163,771
-8,105
| -5% | -$166K |
|
1688
Cimpress
CMPR
$2.31B
| $3.05M | ﹤0.01% |
30,502
-3,297
| -10% | -$325K |
|
1689
QuinStreet
QNST
$1.21B
| $3.05M | ﹤0.01% |
150,428
+2,673
| +2% | +$60.1K |
|
|
SASR
1690
DELISTED
Sandy Spring Bancorp Inc
SASR
| $3.05M | ﹤0.01% |
70,324
-5,145
| -7% | -$196K |
|
|
DMC
1691
Del Monte Corp
DMC
$1.45B
| $3.04M | ﹤0.01% |
106,307
+828
| +0.8% | +$22.1K |
|
|
CCXI
1692
DELISTED
ChemoCentryx, Inc.
CCXI
| $3.04M | ﹤0.01% |
59,407
-7,231
| -11% | -$435K |
|
1693
Shoals Technologies Group
SHLS
$1.5B
| $3.04M | ﹤0.01% |
+87,288
| New | +$3.09M |
|
1694
CorVel
CRVL
$3.19B
| $3.04M | ﹤0.01% |
88,737
+1,287
| +1% | +$44.8K |
|
1695
Hamilton Lane
HLNE
$5.57B
| $3.03M | ﹤0.01% |
34,237
-2,147
| -6% | -$181K |
|
|
FOLD
1696
DELISTED
Amicus Therapeutics
FOLD
| $3.03M | ﹤0.01% |
306,827
-31,780
| -9% | -$492K |
|
|
MFA
1697
MFA Financial
MFA
$933M
| $3.03M | ﹤0.01% |
186,005
-9,360
| -5% | -$149K |
|
1698
Moelis & Co
MC
$4.94B
| $3.02M | ﹤0.01% |
55,127
-8,384
| -13% | -$449K |
|
1699
Brookfield Infrastructure
BIPC
$4.85B
| $3.02M | ﹤0.01% |
59,384
-6,684
| -10% | -$302K |
|
1700
Haverty Furniture Companies
HVT
$454M
| $3.02M | ﹤0.01% |
81,203
+23,434
| +41% | +$810K |
|
Similar funds
VAM
RhumbLine Advisers's Q1 2021 Portfolio in Review
As of Q1 2021, RhumbLine Advisers held 3,102 positions worth $73.6B, up 1.6% from $72.5B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
RhumbLine Advisers withdrew a net $3.6B in Q1 2021, closing 100 positions and reducing 2,114 holdings. Its most notable exit was Tiffany & Co., an estimated $26.8M position sold in full.
By sector, the portfolio is most concentrated in Technology at 23% of assets, down from 24% a quarter earlier, followed by Financials and Healthcare.
Against the trend, RhumbLine Advisers opened a new position in NXP Semiconductors worth $42.7M.
- RhumbLine Advisers's largest Q1 2021 buy was NXP Semiconductors: 211,843 shares worth $42.7M.
- RhumbLine Advisers added most to International Flavors & Fragrances in Q1 2021, an estimated $27.4M increase.
- RhumbLine Advisers's biggest Q1 2021 reduction was Apple, cutting an estimated $269M.
- RhumbLine Advisers fully exited Tiffany & Co. in Q1 2021, selling an estimated $26.8M.
- RhumbLine Advisers's ten largest holdings make up 21% of its $73.6B portfolio in Q1 2021.
- RhumbLine Advisers opened 50 new positions and closed 100 in Q1 2021.
- RhumbLine Advisers's portfolio value rose 1.6% quarter-over-quarter to $73.6B.
Based on RhumbLine Advisers's 13F filing for Q1 2021, filed 6 May 2021.